These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36679936)

  • 1. Revaccination in Age-Risk Groups with Sputnik V Is Immunologically Effective and Depends on the Initial Neutralizing SARS-CoV-2 IgG Antibodies Level.
    Godkov MA; Ogarkova DA; Gushchin VA; Kleymenov DA; Mazunina EP; Bykonia EN; Pochtovyi AA; Shustov VV; Shcheblyakov DV; Komarov AG; Tsibin AN; Zlobin VI; Logunov DY; Gintsburg AL
    Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines: results of a pilot clinical study.
    Stoma I; Korsak K; Voropaev E; Osipkina O; Kovalev A
    Heliyon; 2023 Nov; 9(11):e21877. PubMed ID: 38027828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients.
    Laham G; Martínez AP; Rojas Gimenez W; Amaya L; Abib A; Echegoyen N; Díaz C; Lucero A; Martelli A; Videla C; Neukam K; Di Lello FA
    J Nephrol; 2023 Apr; 36(3):861-872. PubMed ID: 36152219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lasting SARS-CoV-2 specific IgG Antibody response in health care workers from Venezuela, 6 months after vaccination with Sputnik V.
    Claro F; Silva D; Pérez Bogado JA; Rangel HR; de Waard JH
    Int J Infect Dis; 2022 Sep; 122():850-854. PubMed ID: 35690364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal Follow-Up of the Immunity to SARS-CoV-2 in Health Care Workers in Argentina: Persistence of Humoral Response and Neutralizing Capacity after Sputnik V Vaccination.
    Castro EF; Acosta J; Moriena L; Rios Medrano M; Tejerina Cibello M; Codino E; Taborda MÁ; Álvarez DE; Cavatorta AL
    mSphere; 2023 Jun; 8(3):e0066222. PubMed ID: 37070983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm's COVID-19 Vaccines.
    Adjobimey T; Meyer J; Sollberg L; Bawolt M; Berens C; Kovačević P; Trudić A; Parcina M; Hoerauf A
    Front Immunol; 2022; 13():917905. PubMed ID: 35799790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19.
    Kaznadzey A; Tutukina M; Bessonova T; Kireeva M; Mazo I
    Front Immunol; 2022; 13():797918. PubMed ID: 35493476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of BNT162b2 Vaccine Booster Dose in Patients With Inflammatory Bowel Disease Receiving Infliximab Combination Therapy: A Prospective Observational Study.
    Shehab M; Alrashed F; Alfadhli A; Alsayegh A; Aldallal U; Alsayegh M; Cherian P; Alkhair I; Thanaraj TA; Channanath A; Dashti AA; Albanaw A; Ali H; Abu-Farha M; Abubaker J; Al-Mulla F
    Front Med (Lausanne); 2022; 9():933996. PubMed ID: 35860742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoglobulin G antibody response to the Sputnik V vaccine: previous SARS-CoV-2 seropositive individuals may need just one vaccine dose.
    Claro F; Silva D; Rodriguez M; Rangel HR; de Waard JH
    Int J Infect Dis; 2021 Oct; 111():261-266. PubMed ID: 34343704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study].
    Özgür D; Tütüncü EE
    Mikrobiyol Bul; 2022 Jan; 56(1):36-48. PubMed ID: 35088958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals.
    Ogrič M; Žigon P; Podovšovnik E; Lakota K; Sodin-Semrl S; Rotar Ž; Čučnik S
    Front Immunol; 2022; 13():876533. PubMed ID: 35711413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterologous gam-COVID-vac (sputnik V)/mRNA-1273 (moderna) vaccination induces a stronger humoral response than homologous sputnik V in a real-world data analysis.
    Pereson MJ; Amaya L; Neukam K; Baré P; Echegoyen N; Badano MN; Lucero A; Martelli A; Garcia GH; Videla C; Martínez AP; Di Lello FA
    Clin Microbiol Infect; 2022 Oct; 28(10):1382-1388. PubMed ID: 35595128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memory B Cells Induced by Sputnik V Vaccination Produce SARS-CoV-2 Neutralizing Antibodies Upon
    Byazrova MG; Kulemzin SV; Astakhova EA; Belovezhets TN; Efimov GA; Chikaev AN; Kolotygin IO; Gorchakov AA; Taranin AV; Filatov AV
    Front Immunol; 2022; 13():840707. PubMed ID: 35280987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates.
    Tukhvatulin AI; Gordeychuk IV; Dolzhikova IV; Dzharullaeva AS; Krasina ME; Bayurova EO; Grousova DM; Kovyrshina AV; Kondrashova AS; Avdoshina DV; Gulyaev SA; Gulyaeva TV; Moroz AV; Illarionova VV; Zorkov ID; Iliukhina AA; Shelkov AY; Botikov AG; Erokhova AS; Shcheblyakov DV; Esmagambetov IB; Zubkova OV; Tokarskaya EA; Savina DM; Vereveyko YR; Ungur AS; Naroditsky BS; Ishmukhametov AA; Logunov DY; Gintsburg AL
    Emerg Microbes Infect; 2022 Dec; 11(1):2229-2247. PubMed ID: 36031930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections.
    Macrae K; Martinez-Cajas J; Bessai K; Abdulhamed A; Gong Y
    Curr Oncol; 2022 Sep; 29(10):7059-7071. PubMed ID: 36290831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the Previous History of the SARS-CoV-2 Infections on Antibody Levels among Sputnik V Vaccinated Healthcare Workers.
    Yaghoubi A; Asli S; Parhizkar M; Mohammadpour M; Khorsand A; Yousefi M; Bamdad T; Amel Jamehdar S
    Iran J Immunol; 2023 Mar; 20(1):76-82. PubMed ID: 36932965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines.
    Nanthapisal S; Puthanakit T; Jaru-Ampornpan P; Nantanee R; Sodsai P; Himananto O; Sophonphan J; Suchartlikitwong P; Hiransuthikul N; Angkasekwinai P; Tangsathapornpong A; Hirankarn N;
    Vaccine; 2022 Apr; 40(18):2551-2560. PubMed ID: 35341647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort.
    Blanco S; Salomé Konigheim B; Diaz A; Spinsanti L; Javier Aguilar J; Elisa Rivarola M; Beranek M; Collino C; MinSalCba Working Group ; Fcm-Unc Working Group ; Diaz M; Gabriela Barbás M; Mangeaud A; Verónica Gallego S
    Vaccine; 2022 Jan; 40(5):811-818. PubMed ID: 34953609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.